Deferasirox Tablet, For Suspension
NDC Package 68462-496-90
Package Information
Deferasirox tablets is for oral suspension are contraindicated in patients with: •Estimated GFR less than 40 mL/min/1.73 m2 [see Dosage and Administration (Error! Hyperlink reference not valid.), Warnings and Precautions (Error! Hyperlink reference not valid.)]; •Poor performance status [see Warnings and Precautions (Error! Hyperlink reference not valid., Error! Hyperlink reference not valid.)];•High-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy);•Advanced malignancies [see Warnings and Precautions (Error! Hyperlink reference not valid., Error! Hyperlink reference not valid.)];•Platelet counts less than 50 x 109/L [see Warnings and Precautions (Error! Hyperlink reference not valid., Error! Hyperlink reference not valid.)];Known hypersensitivity to deferasirox or any component of deferasirox tablets for oral suspension [see Warnings and Precautions (Error! Hyperlink reference not valid.), Adverse Reactions (Error! Hyperlink reference not valid.)]. This formulation utilizes a tablet, for suspension delivery system. Marketed by Glenmark Pharmaceuticals Inc., Usa, this product is identified by NDC 68462-496 and is authorized under FDA application ANDA209433.
Identification & Billing
- RxCUI: 597768 - deferasirox 125 MG Tablet for Oral Suspension
- RxCUI: 597770 - deferasirox 250 MG Tablet for Oral Suspension
- RxCUI: 597772 - deferasirox 500 MG Tablet for Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68462 - Glenmark Pharmaceuticals Inc., Usa
- 68462-496 - Deferasirox
- 68462-496-90 - 90 TABLET, FOR SUSPENSION in 1 BOTTLE
- 68462-496 - Deferasirox
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68462-496). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68462-496-90 identifies a specific commercial package of 90 tablet, for suspension in 1 bottle of Deferasirox, a human prescription drug labeled by Glenmark Pharmaceuticals Inc., Usa. This tablet, for suspension is formulated for oral use and contains deferasirox as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glenmark Pharmaceuticals Inc., Usa on January 06, 2020. The current certification is valid through December 31, 2027.
How is this Glenmark Pharmaceuticals Inc., Usa product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68462049690. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.